ABSTRACT
AIM: The aim of this study was to establish normal values for parotid gland (PG) and submandibular-sublingual salivary gland complex (SSC) uptake of 99mtechnetium pertechnetate (99mTcO4) as a function of age, sex and circadian rhythm in mice. METHODS: In 12 female (F) and 12 male (M) C57BL/6N mice, nine consecutive SPECT images of 10â min each were acquired as dynamic acquisitions beginning 5â min after intravenous injection of 80 MBq 99mTcO4. Each mouse was imaged in follow-up studies at 1, 3, 6, 12 and 24 months of age. In order to assess for physiologic changes related to circadian rhythm, animals were imaged during light (sleeping phase) as well as during night conditions (awake phase). The percentage tracer uptake of the injected activity is expressed as median %ID. RESULTS: Maximum 99mTcO4 uptake occurred earlier in PG at 11â min compared to SSC at 79â min (pâ <â 0.001). No significant effect of circadian rhythm was observed in PG (pâ =â 0.64) and SSC uptake (pâ =â 0.27). With aging, 99mTcO4 uptake significantly decreased for PG (pâ <â 0.001) while it increased for SSC (pâ <â 0.001). F (0.5) had a significantly higher PG uptake than M (0.3; pâ <â 0.001) up to an age of 24 months. However, SSC uptake of F (4.6) was higher than that of M (3.8; pâ =â 0.014) only at the age of 1 month. Thereafter, F (5.6) had lower SSC uptake than M (9.2; pâ <â 0.001) from 3 months onwards. Normalizing %ID to gland volume showed that F had a significantly higher uptake (%ID/mm3) in both PG (F 0.013; M 0.007; pâ <â 0.001) and in SSC (F 0.110; M 0.075; pâ <â 0.001). CONCLUSION: Uptake patterns differed among PG and SSC with a significant impact of age and sex while circadian rhythm had no significant influence. Therefore, design of salivary gland studies in mice using 99mTcO4 should consider age and sex as relevant factors.
Subject(s)
Aging/metabolism , Circadian Rhythm , Parotid Gland/metabolism , Sex Characteristics , Sodium Pertechnetate Tc 99m/metabolism , Submandibular Gland/metabolism , Tomography, Emission-Computed, Single-Photon/standards , Animals , Biological Transport , Female , Male , Mice , Mice, Inbred C57BL , Parotid Gland/diagnostic imaging , Reference Values , Submandibular Gland/diagnostic imagingABSTRACT
Disturbed magnesium (Mg(2+)) homoeostasis and increased levels of OS (oxidative stress) are associated with poor clinical outcomes in patients suffering from neurodegenerative, cardiovascular and metabolic diseases. Data from clinical and animal studies suggest that MD (Mg(2+) deficiency) is correlated with increased production of ROS (reactive oxygen species) in cells, but a straightforward causal relationship (including molecular mechanisms) between the two conditions is lacking. The multifactorial protein PARK7/DJ-1 is a major antioxidant protein, playing a key role in cellular redox homoeostasis, and is a positive regulator of AR (androgen receptor)-dependent transcription. SLC41A1 (solute carrier family 41 member 1), the gene encoding a ubiquitous cellular Mg(2+)E (Mg(2+)efflux) system, has been shown to be regulated by activated AR. We hypothesize that overexpression/up-regulation of PARK7/DJ-1, attributable to OS and related activation of AR, is an important event regulating the expression of SLC41A1 and consequently, modulating the Mg(2+)E capacity. This would involve changes in the transcriptional activity of PARK7/DJ-1, AR and SLC41A1, which may serve as biomarkers of intracellular MD and may have clinical relevance. Imipramine, in use as an antidepressant, has been shown to reduce the Mg(2+)E activity of SLC41A1 and OS. We therefore hypothesize further that administration of imipramine or related drugs will be beneficial in MD- and OS-associated diseases, especially when combined with Mg(2+) supplementation. If proved true, the OS-responsive functional axis, PARK7/DJ-1-AR-SLC41A1, may be a putative mechanism underlying intracellular MD secondary to OS caused by pro-oxidative stimuli, including extracellular MD. Furthermore, it will advance our understanding of the link between OS and MD.
Subject(s)
Cardiovascular Diseases/etiology , Intracellular Signaling Peptides and Proteins/metabolism , Magnesium Deficiency/etiology , Metabolic Diseases/etiology , Neurodegenerative Diseases/etiology , Oncogene Proteins/metabolism , Oxidative Stress , Signal Transduction , Animals , Cardiovascular Diseases/metabolism , Cardiovascular Diseases/prevention & control , Cation Transport Proteins/antagonists & inhibitors , Cation Transport Proteins/metabolism , Chronic Disease , Humans , Imipramine/therapeutic use , Magnesium Deficiency/drug therapy , Magnesium Deficiency/metabolism , Metabolic Diseases/metabolism , Metabolic Diseases/prevention & control , Molecular Targeted Therapy , Neurodegenerative Diseases/metabolism , Neurodegenerative Diseases/prevention & control , Oxidative Stress/drug effects , Protein Deglycase DJ-1 , Receptors, Androgen/metabolism , Risk Factors , Up-RegulationABSTRACT
BACKGROUND/AIMS: In diabetic nephropathy (DN), the current angiotensin-II-blocking pharmacotherapy is frequently failing. For diabetic cardiomyopathy (DC), there is no specific remedy available. Relaxin-2 (Rlx) - an anti-fibrotic, anti-inflammatory, and vasoprotecting peptide is a candidate drug for both. METHODS: Low-dose (32 µg/kg/day) and high-dose (320 µg/kg/day) Rlx were tested against vehicle (n = 20 each) and non-diabetic controls (n = 14) for 12 weeks in a model of type-1 diabetes induced in endothelial nitric oxide synthase knock-out (eNOS-KO) mice by intraperitoneal injection of streptozotocin. RESULTS: Diabetic animals showed normal plasma creatinine, markedly increased albuminuria and urinary malonyldialdehyde, elevated relative kidney weight, glomerulosclerosis, and increased glomerular size, but no relevant interstitial fibrosis. Neither dose of Rlx affected these changes although the drug was active and targeted plasma levels were achieved. Of note, we found no activation of the renal TGF-ß pathway in this model. In the hearts of diabetic animals, no fibrotic alterations indicative of DC could be determined which precluded testing of the initial hypothesis. CONCLUSIONS: We investigated a model showing early DN without overt tubulointerstitial fibrosis and activation of the TGF-ß-Smad-2/3 pathway. In this model, Rlx proved ineffective; however, the same may not apply to other models and types of diabetes.
Subject(s)
Diabetes Mellitus, Type 1/drug therapy , Diabetic Nephropathies/drug therapy , Disease Models, Animal , Relaxin/therapeutic use , Animals , Diabetes Mellitus, Type 1/pathology , Diabetic Nephropathies/pathology , Male , Mice , Mice, Inbred C57BL , Mice, KnockoutABSTRACT
Butyrate production in the large intestine and ruminant forestomach depends on bacterial butyryl-CoA/acetate-CoA transferase activity and is highest when fermentable fiber and nonstructural carbohydrates are balanced. Gastrointestinal epithelia seem to use butyrate and butyrate-induced endocrine signals to adapt proliferation, apoptosis, and differentiation to the growth of the bacterial community. Butyrate has a potential clinical application in the treatment of inflammatory bowel disease (IBD; ulcerative colitis). Via inhibited release of tumor necrosis factor α and interleukin 13 and inhibition of histone deacetylase, butyrate may contribute to the restoration of the tight junction barrier in IBD by affecting the expression of claudin-2, occludin, cingulin, and zonula occludens poteins (ZO-1, ZO-2). Further evaluation of the molecular events that link butyrate to an improved tight junction structure will allow for the elucidation of the cofactors affecting the reliability of butyrate as a clinical treatment tool.